Loading...
XJPX
4978
Market cap76mUSD
Jul 10, Last price  
129.00JPY
1D
1.57%
1Q
-27.93%
Jan 2017
-70.00%
IPO
-96.48%
Name

ReproCell Inc

Chart & Performance

D1W1MN
XJPX:4978 chart
P/E
P/S
5.66
EPS
Div Yield, %
Shrs. gr., 5y
5.80%
Rev. gr., 5y
11.67%
Revenues
2.23b
-25.02%
278,108,000316,525,000420,078,000460,950,000567,001,0001,066,374,0001,257,812,000926,255,0001,088,527,0001,199,909,0001,286,284,0002,234,568,0002,953,272,0002,426,817,0002,978,627,0002,233,519,000
Net income
-592m
L
-34,890,000-22,206,0005,869,000-133,923,000-451,793,000-1,961,351,000-911,664,000-2,172,046,000-601,425,000-1,016,520,000-812,573,000-575,095,000-305,313,000-31,415,000103,245,000-591,693,000
CFO
-384m
L
-23,896,000-13,076,000-375,000-39,042,000-626,798,000-614,376,000-775,025,000-636,720,000-554,831,000-689,803,000-648,883,000-246,244,000-140,534,000-11,451,0006,287,000-383,526,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Established in 2003 and headquartered in Yokohama, Japan, ReproCELL Incorporated operates as a prominent firm specializing in stem cell research. The company furnishes an extensive portfolio of products crucial for various stem cell applications, including a diverse array of specialized reagents for RNA reprogramming, cell growth (such as small molecules, growth factors, and cytokines), cell characterization (like antibodies and staining kits), cell culture (including pluripotent stem cell media and cell substrates), and cell handling (such as cryopreservation media, dissociation solutions, and transfection reagents). Furthermore, ReproCELL provides differentiated induced pluripotent stem cells (iPSCs), related components like feeder cells and induced neurons, 3D cell culture systems, and general laboratory consumables. Complementing its product lines, the company offers a comprehensive suite of services, spanning preclinical genomics, dedicated stem cell research, drug development support (encompassing efficacy, safety, and ADME analyses), access to human tissue samples, therapeutic pipeline development, and a range of clinical services, including laboratory diagnostics and the creation of GMP iPSC master cell banks.
IPO date
Jun 26, 2013
Employees
92
Domiciled in
JP
Incorporated in
JP

Valuation

Title
JPY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2026‑032025‑032024‑032023‑032022‑032021‑032020‑032019‑032018‑032017‑03
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT